$USPH

U S PHYSICAL THERAPY INC /NV (USPH): Results of Operations and Financial Condition

U S PHYSICAL THERAPY INC /NV (USPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTACT: U.S. Physical Therapy, Inc. Jason Curtis, Interim Chief Financial Officer email: jcurtis@usph.com Chris Reading, Chief Executive Officer (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424 USPH Reports Second Quarter 2026 Results, Reaffirms Full Yea

Original reporting
Published Aug 6, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$USPH
Neutral
medium confidence
Mentioned
$USPH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$USPHNeutralMed
01

Why it matters

The key tradable elements are the reported Q2/YTD operating metrics, the stated integration milestone (31 clinics completed, 39 expected in Q3), and management’s expectation for accelerating adjusted EBITDA improvement in 2H 2026 and into 2027.

02

Market read

This is a company-specific earnings-style update with operational KPIs and a stated execution timeline for hospital-affiliated clinic integrations, which can drive revisions to 2H 2026 and 2027 expectations.

03

What to watch

GAAP net income and EPS fell year over year, and cash declined while debt increased; traders may focus on leverage and liquidity alongside operating KPIs.

Relevance 7/10Novelty 6/10Timing: after-hours filing of Q2 2026 results and guidance reaffirmation

Background

U.S. Physical Therapy, Inc. filed an 8-K with its Q2 2026 operating results and commentary on integrating hospital-affiliated clinics and operational initiatives.

Company-level read

Ticker impact

$USPHNeutralMedium confidence
Context

USPH reported Q2 2026 results and reaffirmed full-year guidance, including integration progress of 31 hospital-affiliated clinics and updated margin drivers.

Expected impact

Near-term trading likely hinges on whether investors view the margin compression and GAAP EPS decline as temporary versus the credibility of the 2H 2026 adjusted EBITDA acceleration plan.

Evidence & confidence

The filing provides multiple operating KPIs (revenue, visits, revenue per visit, margins) plus balance-sheet and capital allocation updates, but it does not include explicit new full-year numeric guidance in the provided excerpt.

Market effects

Outpatient therapy operators may see read-through on demand durability (patient visits growth) and margin sensitivity to health benefit costs.

No specific regional catalyst beyond nationwide clinic integration execution.

Limited global relevance; primarily a US healthcare services operator update.

Counterpoint

Investors may discount the 2H 2026 adjusted EBITDA acceleration if the Q2 margin decline from health benefit costs signals structural cost pressure rather than a one-off timing issue.

Key entities

  • U.S. Physical Therapy, Inc.

    NYSE-listed outpatient physical therapy operator reporting Q2 2026 results and reaffirming full-year guidance.

  • Jason Curtis

    Interim CFO referenced in the filing contact block.

  • Chris Reading

    CEO/Chairman quoted on integration progress and 2H 2026 adjusted EBITDA expectations.

Related articles

$USPHMed

US Physical Therapy (USPH) Taps A Global Finance Veteran As CFO

US Physical Therapy (USPH) appointed Nchacha Etta as CFO, effective September 1. Etta previously held CFO roles at Omnicell (OMCL) and Johnson & Johnson Vision. USPH reported Q2 2026 revenue of $214.1M, up 8.5%, but net income fell to $9.9M from $12.4M. The company reaffirmed full-year adjusted EBITDA guidance of $102M-$106M.

$USPHMedAI 8/10

USPH (USPH) Q2 2026 Earnings Call Transcript

US Physical Therapy (USPH) discussed its Q2 2026 results and hospital-affiliation rollout. The company said Q2 revenue rose 8.5% to $214M, PT revenue rose 8.4% to $182M, and visits increased 6.6% to 1.662M. Net rate was $107.59. It cited $3.2M higher self-insured health care costs and expects clinic transitions to continue into Q3.

$RLGTMed

Why Radiant Logistics Stock Topped the Market on Tuesday

Radiant Logistics (RLGT) stock rose nearly 20% after reporting fiscal Q4 revenue of $261M (up 19% YoY) and GAAP net income of $7.5M (up 53% YoY), beating analyst estimates. The company attributed gains to increased U.S. forwarding and international airfreight volumes. However, it warned of global economic uncertainty and potential market volatility.

$ORCLMedAI 9/10

A $90 Billion Reason to Buy Oracle Stock Now

Oracle reported Q1 FY2027 earnings, beating expectations with $19.35B revenue (up 29.6% YoY) and $1.92 adjusted EPS (up 30.6% YoY). Cloud revenue surged 61.5% to $11.6B, with OCI growing 121% YoY. Oracle expects Q2 revenue growth of 30-34% and full-year revenue of at least $90B. Analysts maintain bullish views, with an average price target of $247.19.

$PPGHighAI 8/10

Is PPG Industries Stock Underperforming the Dow?

PPG Industries reported Q2 adjusted EPS of $2.23, missing estimates, and revenue of $4.5B, beating forecasts. Shares fell 6% post-results. The company expects full-year adjusted EPS of $7.70-$8.10. Analysts rate PPG a 'Moderate Buy' with a mean price target of $126.28, implying 20.1% upside.